Champions Oncology, Inc. (CSBR): Operating Cash Flow
-$4.47M
Year ended 2026-04-30
-$5.56M
Trailing 12 months to 2026-07-31
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | -$4.47M | n/m | 2026-07-27, From 2025-05-01 |
| 2025-04-30 | $7.39M | n/m | 2026-07-27, From 2024-05-01 |
| 2024-04-30 | -$6.14M | n/m | 2025-07-23, From 2023-05-01 |
| 2023-04-30 | $3.97M | -38.9% | 2024-07-19, From 2022-05-01 |
| 2022-04-30 | $6.50M | n/m | 2023-07-24, From 2021-05-01 |
| 2021-04-30 | -$1.68M | n/m | 2022-07-22, From 2020-05-01 |
| 2020-04-30 | $2.90M | +56.0% | 2021-07-26, From 2019-05-01 |
| 2019-04-30 | $1.86M | n/m | 2020-07-28, From 2018-05-01 |
| 2018-04-30 | -$1.23M | n/m | 2019-07-29, From 2017-05-01 |
| 2017-04-30 | -$2.84M | n/m | 2018-07-30, From 2016-05-01 |
| 2016-04-30 | -$6.41M | n/m | 2017-07-28, From 2015-05-01 |
| 2015-04-30 | -$9.63M | n/a | 2016-07-29, From 2014-05-01 |
| No annual figure between 2013-04-30 and 2015-04-30. | |||
| 2013-04-30 | -$4.29M | n/m | 2013-07-26, From 2012-05-01 |
| 2012-04-30 | -$5.23M | n/m | 2013-07-26, From 2011-05-01 |
| 2011-04-30 | -$54.0K | n/a | 2012-07-18, From 2010-05-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$4.47M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$58.13M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$11.99M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$391.78M | n/m |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $29.61M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $31.63M | -36.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | -$371.81M | n/m |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$283.57M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | -$12.47M | n/m |
Compare CSBR, IVVD, PLX, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗